Publication

The long road: improving outcome in elderly "unfit" AML?

Lowenberg, B. & Huls, G., 11-Jun-2020, In : Blood. 135, 24, p. 2114-2115 3 p.

Research output: Contribution to journalEditorialAcademicpeer-review

APA

Lowenberg, B., & Huls, G. (2020). The long road: improving outcome in elderly "unfit" AML? Blood, 135(24), 2114-2115. https://doi.org/10.1182/blood.2020005651

Author

Lowenberg, Bob ; Huls, Gerwin. / The long road : improving outcome in elderly "unfit" AML?. In: Blood. 2020 ; Vol. 135, No. 24. pp. 2114-2115.

Harvard

Lowenberg, B & Huls, G 2020, 'The long road: improving outcome in elderly "unfit" AML?', Blood, vol. 135, no. 24, pp. 2114-2115. https://doi.org/10.1182/blood.2020005651

Standard

The long road : improving outcome in elderly "unfit" AML? / Lowenberg, Bob; Huls, Gerwin.

In: Blood, Vol. 135, No. 24, 11.06.2020, p. 2114-2115.

Research output: Contribution to journalEditorialAcademicpeer-review

Vancouver

Lowenberg B, Huls G. The long road: improving outcome in elderly "unfit" AML? Blood. 2020 Jun 11;135(24):2114-2115. https://doi.org/10.1182/blood.2020005651


BibTeX

@article{ca90d8f312254538bb9c11aaf4b037f6,
title = "The long road: improving outcome in elderly {"}unfit{"} AML?",
abstract = "In this issue of Blood, Wei et al(1) report the results of a prospective randomized placebo-controlled trial that presents formal evidence of an overall survival benefit of adding venetoclax to low-dose cytarabine (LDAC) in elderly patients with newly diagnosed acute myeloid leukemia (AML) not considered eligible for intensive cytotoxic treatment.",
keywords = "LOW-DOSE CYTARABINE, PLACEBO",
author = "Bob Lowenberg and Gerwin Huls",
year = "2020",
month = "6",
day = "11",
doi = "10.1182/blood.2020005651",
language = "English",
volume = "135",
pages = "2114--2115",
journal = "Blood",
issn = "0006-4971",
publisher = "AMER SOC HEMATOLOGY",
number = "24",

}

RIS

TY - JOUR

T1 - The long road

T2 - improving outcome in elderly "unfit" AML?

AU - Lowenberg, Bob

AU - Huls, Gerwin

PY - 2020/6/11

Y1 - 2020/6/11

N2 - In this issue of Blood, Wei et al(1) report the results of a prospective randomized placebo-controlled trial that presents formal evidence of an overall survival benefit of adding venetoclax to low-dose cytarabine (LDAC) in elderly patients with newly diagnosed acute myeloid leukemia (AML) not considered eligible for intensive cytotoxic treatment.

AB - In this issue of Blood, Wei et al(1) report the results of a prospective randomized placebo-controlled trial that presents formal evidence of an overall survival benefit of adding venetoclax to low-dose cytarabine (LDAC) in elderly patients with newly diagnosed acute myeloid leukemia (AML) not considered eligible for intensive cytotoxic treatment.

KW - LOW-DOSE CYTARABINE

KW - PLACEBO

U2 - 10.1182/blood.2020005651

DO - 10.1182/blood.2020005651

M3 - Editorial

VL - 135

SP - 2114

EP - 2115

JO - Blood

JF - Blood

SN - 0006-4971

IS - 24

ER -

ID: 128532076